Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: A randomized, open-label trial

American Journal of Transplantation

Volumn 9, Issue 11, 2009, Pages 2505-2513

  Wlodarczyk, Z ^a   Squifflet, J P ^b   Ostrowski, M ^c   Rigotti, P ^d   Stefoni, S ^e   Citterio, F ^f   Vanrenterghem, Y ^g   Kramer B K ^h   Abramowicz, D ⁱ   Oppenheimer, F ^j   Pietruck, F ^k   Russ, G ^l   Karpf, C ^m   Undre, N ⁿ  

^a Antoni Jurasz University Hospital   (Poland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Klinika Chirurgii Ogolnej i N   (Poland)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ ERASME HOSPITAL   (Belgium)

^j HOSPITAL CLÍNIC   (Spain)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l QUEEN ELIZABETH HOSPITAL   (Australia)

^m Astellas GmbH   (Germany)

ⁿ ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

more..

Author keywords

Kidney transplantation; Once daily tacrolimus; Pharmacokinetics; Prolonged release tacrolimus; Tacrolimus

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EUROPE; EVALUATION; FEMALE; HUMAN; HYPERTENSION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 70350125161     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02794.x     Document Type: Article

References (15)

1. Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: Noncompliance masquerading as chronic rejection. Transplant Proc 1999 31 (Suppl. 4A 21S 23S.
2. Matas AJ, Humar A, Gillingham KJ et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002 62 : 704 714.
3. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: A systematic review. Transplantation 2004 77 : 769 789.
4. Weng FL, Israni AK, Joffe MM et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005 16 : 1839 1848.
5. Ichimaru N, Kakuta Y, Abe T et al. Treatment adherence in renal transplant recipients: A questionnaire survey on immunosuppressants. Transplant Proc 2008 40 : 1362 1365.
6. Scott L, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003 63 : 1247 1297.
7. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004 43 : 623 653.
8. Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European Consensus Conference. Ther Drug Monit 2009 31 : 139 152.
9. Alloway R, Steinberg S, Khahil K et al. Conversion of stable kidney transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified-release tacrolimus-based regimen. Transplant Proc 2005 37 : 867 870. (Pubitemid 40590728)
10. Florman S, Alloway R, Kalayoglu M et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005 37 : 1211 1213. (Pubitemid 40590839)
11. Alloway R, Vanhaecke J, Undre N, For the Modified Release Tacrolimus Heart Study Group. Conversion of stable heart transplant recipients from twice-daily Prograf to once-daily modified-release tacrolimus. Transpl Int 2005 18 (Suppl 1 75 (Abstract PO-083).
12. Alak AM, Moy S, Cook M et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. J Pharm Biomed Anal 1997 16 : 7 13.
13. van Duijnhoven E, Christiaans M, Schafer A, Undre N, van Hooff J. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998 30 : 1266 1267.
14. van Duijnhoven E, Christiaans M, Schafer A, Undre N, Stevenson P, van Hooff J. The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. Transplant Proc 1998 30 : 1268 1270.
15. Mendonza A, Zahir H, Gohh R, Akhlaghi F. Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007 29 : 391 398.